Is Wilhelmina International, Inc. overvalued or undervalued?

As of 31 October 2025, the valuation grade for Wilhelmina International, Inc. has moved from very expensive to attractive, indicating a shift towards a more favorable assessment. The company appears undervalued, supported by a P/E ratio of 21, a price-to-book value of 0.83, and an EV to EBITDA ratio of 8.84. In comparison, its peer Coya Therapeutics, Inc. has a P/E of approximately 18.70, suggesting that Wilhelmina's valuation is relatively competitive within its industry.
Despite the attractive valuation metrics, the company's recent stock performance has been underwhelming, with a year-to-date return of -15.49% compared to a positive return of 16.30% for the S&P 500. This stark contrast in returns over the same period reinforces the notion that Wilhelmina International, Inc. may be undervalued relative to its market performance and peer comparisons.